Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter marketing option Intercept-ed, may precede U.S. kick-off

This article was originally published in The Gray Sheet

Executive Summary

Cerus will pay $39 mil to Baxter to re-acquire rights to Intercept blood pathogen inactivation system for red cell applications in the U.S. and plasma applications in the U.S. and Canada, under a restructured co-marketing agreement announced Feb. 3. Baxter will continue working with Cerus to bring Intercept to the European market for platelet and plasma applications through at least 2006. The firms will continue to work together on U.S. regulatory approval of platelet applications...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts